Halozyme Therapeutics, Inc.'s stock plummeted by 27% on Friday after management reported that it had halted enrollment and dosing in its phase 2 pancreatic cancer trial of PEGPH20 as a "precautionary measure." The trial was halted at the request of an independent Data Monitoring Committee, or DMC, based on a possible observed difference in thromboembolic (blood clot) events among study participants in the PEGPH20 arm.
Halozyme's management has not released additional information as of this writing, with CEO Dr. Helen Torley merely noting that "We will be providing additional information to the DMC as quickly as possible so they can complete their assessment and we can determine next steps."
In this segment of Friday's market checkup, Motley Fool health care analysts David Williamson and Michael Douglass discuss Halozyme's halted enrollment, the company's overall position, and whether this is a good opportunity to invest in the stock.
Looking for the next great investment opportunity?
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.